Base de dados : MEDLINE
Pesquisa : D27.505.954.600 [Categoria DeCS]
Referências encontradas : 8901 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 891 ir para página                         

  1 / 8901 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29480860
[Au] Autor:Zhu H; Zhao Y; Wang X
[Ad] Endereço:Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, P.R. China.
[Ti] Título:The radiosensitive effect of apatinib for hepatocellular carcinoma patient with big paraspinal metastasis: A case report.
[So] Source:Medicine (Baltimore);97(2):e9598, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Hepatocellular carcinoma (HCC) is a highly invasive cancer associated with great mortality rates. The prognosis of advanced HCC is very poor. PATIENT CONCERNS: Here, we report a HCC patient with a big paraspinal metastasis with 10 cm in diameter who failed the treatment of sorafenib. DIAGNOSES: Sorafenib refractory HCC with big paraspinal metastasis. INTERVENTIONS: The concurrent treatment of apatinib with stereotactic body radiotherapy (SBRT). OUTCOMES: The paraspinal metastasis with 10 cm in diameter showed nearly complete response. LESSONS: We think that the apatinib may be a good choice for HCC and it may function as a radiosensitizer of HCC. However, it warrants further investigation in the future prospective clinical studies.
[Mh] Termos MeSH primário: Carcinoma Hepatocelular/terapia
Neoplasias Hepáticas/terapia
Piridinas/uso terapêutico
Radiossensibilizantes/uso terapêutico
Neoplasias da Coluna Vertebral/secundário
Neoplasias da Coluna Vertebral/terapia
[Mh] Termos MeSH secundário: Adulto
Antineoplásicos/uso terapêutico
Carcinoma Hepatocelular/diagnóstico por imagem
Carcinoma Hepatocelular/patologia
Evolução Fatal
Seres Humanos
Neoplasias Hepáticas/diagnóstico por imagem
Neoplasias Hepáticas/patologia
Masculino
Neoplasias da Coluna Vertebral/diagnóstico por imagem
Carga Tumoral
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Pyridines); 0 (Radiation-Sensitizing Agents); 5S371K6132 (apatinib)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180227
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009598


  2 / 8901 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29365347
[Au] Autor:Tsao MN; Xu W; Wong RK; Lloyd N; Laperriere N; Sahgal A; Rakovitch E; Chow E
[Ad] Endereço:Department of Radiation Oncology, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, Canada, M4N 3M5.
[Ti] Título:Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.
[So] Source:Cochrane Database Syst Rev;1:CD003869, 2018 01 25.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: This is an update to the review published in the Cochrane Library (2012, Issue 4).It is estimated that 20% to 40% of people with cancer will develop brain metastases during the course of their illness. The burden of brain metastases impacts quality and length of survival. OBJECTIVES: To assess the effectiveness and adverse effects of whole brain radiotherapy (WBRT) given alone or in combination with other therapies to adults with newly diagnosed multiple brain metastases. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase to May 2017 and the National Cancer Institute Physicians Data Query for ongoing trials. SELECTION CRITERIA: We included phase III randomised controlled trials (RCTs) comparing WBRT versus other treatments for adults with newly diagnosed multiple brain metastases. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trial quality and abstracted information in accordance with Cochrane methods. MAIN RESULTS: We added 10 RCTs to this updated review. The review now includes 54 published trials (45 fully published reports, four abstracts, and five subsets of data from previously published RCTs) involving 11,898 participants.Lower biological WBRT doses versus controlThe hazard ratio (HR) for overall survival (OS) with lower biological WBRT doses as compared with control (3000 cGy in 10 daily fractions) was 1.21 (95% confidence interval (CI) 1.04 to 1.40; P = 0.01; moderate-certainty evidence) in favour of control. The HR for neurological function improvement (NFI) was 1.74 (95% CI 1.06 to 2.84; P = 0.03; moderate-certainty evidence) in favour of control fractionation.Higher biological WBRT doses versus controlThe HR for OS with higher biological WBRT doses as compared with control (3000 cGy in 10 daily fractions) was 0.97 (95% CI 0.83 to 1.12; P = 0.65; moderate-certainty evidence). The HR for NFI was 1.14 (95% CI 0.92 to 1.42; P = 0.23; moderate-certainty evidence).WBRT and radiosensitisersThe addition of radiosensitisers to WBRT did not confer additional benefit for OS (HR 1.05, 95% CI 0.99 to 1.12; P = 0.12; moderate-certainty evidence) or for brain tumour response rates (odds ratio (OR) 0.84, 95% CI 0.63 to 1.11; P = 0.22; high-certainty evidence).Radiosurgery and WBRT versus WBRT aloneThe HR for OS with use of WBRT and radiosurgery boost as compared with WBRT alone for selected participants was 0.61 (95% CI 0.27 to 1.39; P = 0.24; moderate-certainty evidence). For overall brain control at one year, the HR was 0.39 (95% CI 0.25 to 0.60; P < 0.0001; high-certainty evidence) favouring the WBRT and radiosurgery boost group.Radiosurgery alone versus radiosurgery and WBRTThe HR for local brain control was 2.73 (95% CI 1.87 to 3.99; P < 0.00001; high-certainty evidence)favouring the addition of WBRT to radiosurgery. The HR for distant brain control was 2.34 (95% CI 1.73 to 3.18; P < 0.00001; high-certainty evidence) favouring WBRT and radiosurgery. The HR for OS was 1.00 (95% CI 0.80 to 1.25; P = 0.99; moderate-certainty evidence). Two trials reported worse neurocognitive outcomes and one trial reported worse quality of life outcomes when WBRT was added to radiosurgery.We could not pool data from trials related to chemotherapy, optimal supportive care (OSC), molecular targeted agents, neurocognitive protective agents, and hippocampal sparing WBRT. However, one trial reported no differences in quality-adjusted life-years for selected participants with brain metastases from non-small-cell lung cancer randomised to OSC and WBRT versus OSC alone. AUTHORS' CONCLUSIONS: None of the trials with altered higher biological WBRT dose-fractionation schemes reported benefit for OS, NFI, or symptom control compared with standard care. However, OS and NFI were worse for lower biological WBRT dose-fractionation schemes than for standard dose schedules.The addition of WBRT to radiosurgery improved local and distant brain control in selected people with brain metastases, but data show worse neurocognitive outcomes and no differences in OS.Selected people with multiple brain metastases from non-small-cell lung cancer may show no difference in OS when OSC is given and WBRT is omitted.Use of radiosensitisers, chemotherapy, or molecular targeted agents in conjunction with WBRT remains experimental.Further trials are needed to evaluate the use of neurocognitive protective agents and hippocampal sparing with WBRT. As well, future trials should examine homogeneous participants with brain metastases with focus on prognostic features and molecular markers.
[Mh] Termos MeSH primário: Neoplasias Encefálicas/radioterapia
Neoplasias Encefálicas/cirurgia
[Mh] Termos MeSH secundário: Adulto
Neoplasias Encefálicas/mortalidade
Neoplasias Encefálicas/secundário
Terapia Combinada
Irradiação Craniana/métodos
Irradiação Craniana/mortalidade
Fracionamento de Dose
Seres Humanos
Radiossensibilizantes/uso terapêutico
Radiocirurgia/efeitos adversos
Radiocirurgia/métodos
Ensaios Clínicos Controlados Aleatórios como Assunto
Análise de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Radiation-Sensitizing Agents)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180125
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD003869.pub4


  3 / 8901 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29336987
[Au] Autor:da Costa Araldi IC; Bordin FPR; Cadoná FC; Barbisan F; Azzolin VF; Teixeira CF; Baumhardt T; da Cruz IBM; Duarte MMMF; Bauermann LF
[Ad] Endereço:Laboratory of Experimental Physiology, Center of Health Sciences, Federal University of Santa Maria, Santa Maria, RS, Brazil.
[Ti] Título:The in vitro radiosensitizer potential of resveratrol on MCF-7 breast cancer cells.
[So] Source:Chem Biol Interact;282:85-92, 2018 Feb 25.
[Is] ISSN:1872-7786
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Radiation therapy is commonly applied in breast cancer (BC) patients. However, radioresistance and side effects are limiting factors of this practice. Therefore, studying substances that can enhance the radiation effect and, at the same time, protect normal cells is very relevant. Thus, the aim of this work was to assess the radiosensitizer effect of resveratrol (RV) on BC cells (MCF-7). A high cytotoxic and antiproliferative effect was observed in the treatment with 10 µM of RV + 3 Gy ionizing radiation (IR). Our results indicate that, 24 h after the exposition of cell cultures to RV + IR, an induction of necrosis/senescence has occurred. Furthermore, was observed the activation of extrinsic apoptosis pathway through a decrease of the Bax/Bcl-2 ratio and a high activity of caspase 8. Moreover, our data show that this treatment affected the oxidative cell metabolism, increasing oxidative protein, lipid and membrane damage and also acted to decrease the antioxidant enzymes activity. The antiproliferative effect on 72 h cultures may be associated with a high expression of p53 and an interruption of cell cycle in the S phase. Therefore, our results suggest that RV is a potential radiosensitizer of MCF-7 BC cells.
[Mh] Termos MeSH primário: Neoplasias da Mama/tratamento farmacológico
Radiossensibilizantes/farmacologia
Estilbenos/farmacologia
[Mh] Termos MeSH secundário: Antioxidantes/metabolismo
Apoptose/efeitos dos fármacos
Neoplasias da Mama/metabolismo
Ciclo Celular/efeitos dos fármacos
Linhagem Celular Tumoral
Proliferação Celular/efeitos dos fármacos
Feminino
Seres Humanos
Células MCF-7
Transdução de Sinais/efeitos dos fármacos
Proteína Supressora de Tumor p53/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Radiation-Sensitizing Agents); 0 (Stilbenes); 0 (Tumor Suppressor Protein p53); Q369O8926L (resveratrol)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180117
[St] Status:MEDLINE


  4 / 8901 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28467720
[Au] Autor:Lazzari C; Karachaliou N; Gregorc V; Bulotta A; Gonzalez-Cao M; Verlicchi A; Altavilla G; Rosell R; Santarpia M
[Ad] Endereço:a Department of Oncology, Division of Experimental Medicine , IRCCS San Raffaele , Milan , Italy.
[Ti] Título:Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.
[So] Source:Expert Rev Respir Med;11(6):469-479, 2017 Jun.
[Is] ISSN:1747-6356
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The treatment of lung cancer has radically changed over the last few years. The discovery of druggable oncogenic alterations and the introduction of immunotherapy have provided lung cancer patients with the possibility of more efficient and less toxic therapeutic alternatives than chemotherapy. In the case of lung squamous cell carcinoma (LSCC), the treatment progress is slower than adenocarcinoma, for which several targeted agents have been already approved. The standard first-line therapy for LSCC, in most sites of the world, is platinum-based chemotherapy. After disease progression, these patients now have novel treatment options, including antiangiogenic agents and immune checkpoint blockade. Areas covered: We provide a summary of the recent novelties for the second-line therapy of LSCC, emphasizing on the results of the most important clinical trials that have led to regulatory approvals. Expert commentary: Immune checkpoint inhibitors have changed the therapeutic algorithm for LSCC patients. Other treatment options in the second-line setting include ramucirumab in combination with docetaxel and afatinib. However, we still lack biomarkers to predict which patients could respond better to each treatment. Despite the identification of several actionable molecular alterations, there are no approved targeted agents specific for advanced LSCC. Results from ongoing biomarker-driven studies are eagerly awaited to establish effective treatments for molecularly selected subgroups of patients.
[Mh] Termos MeSH primário: Inibidores da Angiogênese/uso terapêutico
Antineoplásicos/uso terapêutico
Carcinoma de Células Escamosas/tratamento farmacológico
Neoplasias Pulmonares/tratamento farmacológico
Radiossensibilizantes/uso terapêutico
[Mh] Termos MeSH secundário: Anticorpos Monoclonais/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica
Carcinoma de Células Escamosas/patologia
Seres Humanos
Neoplasias Pulmonares/patologia
Quinazolinas/uso terapêutico
Retratamento
Taxoides/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Angiogenesis Inhibitors); 0 (Antibodies, Monoclonal); 0 (Antineoplastic Agents); 0 (Quinazolines); 0 (Radiation-Sensitizing Agents); 0 (Taxoids); 15H5577CQD (docetaxel); 41UD74L59M (afatinib); D99YVK4L0X (ramucirumab)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180131
[Lr] Data última revisão:
180131
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1080/17476348.2017.1326822


  5 / 8901 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28452253
[Au] Autor:Khoshgard K; Kiani P; Haghparast A; Hosseinzadeh L; Eivazi MT
[Ad] Endereço:a Department of Medical Physics, Faculty of Medicine , Kermanshah University of Medical Sciences , Kermanshah , Iran.
[Ti] Título:Radiation dose rate affects the radiosensitization of MCF-7 and HeLa cell lines to X-rays induced by dextran-coated iron oxide nanoparticles.
[So] Source:Int J Radiat Biol;93(8):757-763, 2017 08.
[Is] ISSN:1362-3095
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND PURPOSE: The aim of radiotherapy is to deliver lethal damage to cancerous tissue while preserving adjacent normal tissues. Radiation absorbed dose of the tumoral cells can increase when high atomic nanoparticles are present in them during irradiation. Also, the dose rate is an important aspect in radiation effects that determines the biological results of a given dose. This in vitro study investigated the dose-rate effect on the induced radiosensitivity by dextran-coated iron oxide in cancer cells. MATERIALS AND METHODS: HeLa and MCF-7 cells were cultured in vitro and incubated with different concentrations of dextran-coated iron oxide nanoparticles. They were then irradiated with 6 MV photons at dose rates of 43, 185 and 370 cGy/min. The MTT test was used to obtain the cells' survival after 48 h of irradiations. RESULTS: Incubating the cells with the nanoparticles at concentrations of 10, 40 and 80 µg/ml showed no significant cytotoxicity effect. Dextran-coated iron oxide nanoparticles showed more radiosensitivity effect by increasing the dose rate and nanoparticles concentration. Radiosensitization enhancement factors of MCF-7 and HeLa cells at a dose-rate of 370 cGy/min and nanoparticles' concentration of 80 µg/ml were 1.21 ± 0.06 and 1.19 ± 0.04, respectively. CONCLUSION: Increasing the dose rate of 6 MV photons irradiation in MCF-7 and HeLa cells increases the radiosensitization induced by the dextran-coated iron nanoparticles in these cells.
[Mh] Termos MeSH primário: Dextranos/química
Compostos Férricos/química
Compostos Férricos/farmacologia
Nanopartículas
Dose de Radiação
Radiossensibilizantes/química
Radiossensibilizantes/farmacologia
[Mh] Termos MeSH secundário: Relação Dose-Resposta à Radiação
Compostos Férricos/toxicidade
Células HeLa
Seres Humanos
Células MCF-7
Radiossensibilizantes/toxicidade
Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Dextrans); 0 (Ferric Compounds); 0 (Radiation-Sensitizing Agents); 1K09F3G675 (ferric oxide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:180111
[Lr] Data última revisão:
180111
[Sb] Subgrupo de revista:IM; S
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1080/09553002.2017.1321806


  6 / 8901 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29277765
[Au] Autor:Yang G; Qiu J; Wang D; Tao Y; Song Y; Wang H; Tang J; Wang X; Sun YU; Yang Z; Hoffman RM
[Ad] Endereço:Hangzhou Third Hospital, Hangzhou, P.R. China.
[Ti] Título:Traditional Chinese Medicine Curcumin Sensitizes Human Colon Cancer to Radiation by Altering the Expression of DNA Repair-related Genes.
[So] Source:Anticancer Res;38(1):131-136, 2018 01.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: The aim of the present study was to investigate the radio-sensitizing efficacy of curcumin, a traditional Chinese medicine (TCM) on colon cancer cells in vitro and in vivo. MATERIALS AND METHODS: Human colon cancer HT-29 cells were treated with curcumin (2.5 µM), irradiation (10 Gy) and the combination of irradiation and curcumin. Cell proliferation was assessed using the MTT assay. Apoptotic cells were detected by Annexin V-PE/7-AAD analysis. PCR was performed to determine differential-expression profiling of 95 DNA-repair genes in irradiated cells and cells treated with both irradiation and curcumin. Differentially-expressed genes were confirmed by Western blotting. In vivo radio-sensitizing efficacy of curcumin was assessed in a xenograft mouse model of HT-29 colon cancer. Curcumin was administrated daily by intraperitoneal injection at 20 mg/kg/dose. Mice received irradiation (10 Gy) twice weekly. Apoptosis of the cancer cells following treatment was determined by TUNEL staining. RESULTS: Irradiation induced proliferation inhibition and apoptosis of HT-29 cells in vitro. Concurrent curcumin treatment sensitized the HT-29 tumor to irradiation (p<0.01). DNA repair-related genes CCNH and XRCC5 were upregulated and LIG4 and PNKP downregulated by the combination of curcumin and irradiation compared with irradiation alone (p<0.05). Combined treatment of curcumin and irradiation resulted in a significantly greater tumor-growth inhibition and apoptosis compared to irradiation treatment alone (p<0.01). CONCLUSION: Curcumin sensitizes human colon cancer in vitro and in vivo to radiation. Downregulation of LIG4 and PNKP and upregulation of XRCC5 and CCNH DNA-repair-related genes were involved in the radio-sensitizing efficacy of curcumin in colon cancer.
[Mh] Termos MeSH primário: Neoplasias do Colo/tratamento farmacológico
Neoplasias do Colo/radioterapia
Curcumina/farmacologia
Curcumina/uso terapêutico
Radiossensibilizantes/farmacologia
Radiossensibilizantes/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Apoptose/efeitos dos fármacos
Apoptose/efeitos da radiação
Proliferação Celular/efeitos dos fármacos
Proliferação Celular/efeitos da radiação
Neoplasias do Colo/metabolismo
Neoplasias do Colo/patologia
Ciclina H/genética
Ciclina H/metabolismo
DNA Ligase Dependente de ATP/genética
DNA Ligase Dependente de ATP/metabolismo
Reparo do DNA/genética
Enzimas Reparadoras do DNA/genética
Enzimas Reparadoras do DNA/metabolismo
Feminino
Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos
Regulação Neoplásica da Expressão Gênica/efeitos da radiação
Células HT29
Seres Humanos
Autoantígeno Ku/genética
Autoantígeno Ku/metabolismo
Medicina Tradicional Chinesa
Camundongos Endogâmicos BALB C
Camundongos Nus
Fosfotransferases (Aceptor do Grupo Álcool)/genética
Fosfotransferases (Aceptor do Grupo Álcool)/metabolismo
Carga Tumoral/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CCNH protein, human); 0 (Cyclin H); 0 (LIG4 protein, human); 0 (Radiation-Sensitizing Agents); EC 2.7.1.- (PNKP protein, human); EC 2.7.1.- (Phosphotransferases (Alcohol Group Acceptor)); EC 3.6.4.12 (XRCC5 protein, human); EC 4.2.99.- (Ku Autoantigen); EC 6.5.1.- (DNA Repair Enzymes); EC 6.5.1.1 (DNA Ligase ATP); IT942ZTH98 (Curcumin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171227
[St] Status:MEDLINE


  7 / 8901 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29022496
[Au] Autor:Medhat AM; Azab KS; Said MM; El Fatih NM; El Bakary NM
[Ad] Endereço:1 Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt.
[Ti] Título:Antitumor and radiosensitizing synergistic effects of apigenin and cryptotanshinone against solid Ehrlich carcinoma in female mice.
[So] Source:Tumour Biol;39(10):1010428317728480, 2017 Oct.
[Is] ISSN:1423-0380
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Considerable attention has been paid to the introduction of novel naturally occurring plant-derived radiosensitizer compounds in order to augment the radiation efficacy and improve the treatment outcome of different tumors. This study was therefore undertaken to evaluate the antitumor, antiangiogeneic, and synergistic radiosensitizing effects of apigenin, a dietary flavonoid, and/or cryptotanshinone, a terpenoid isolated from the roots of Salvia miltiorrhiza, against the growth of solid Ehrlich carcinoma in female mice. Apigenin (50 mg/kg body weight) and/or cryptotanshinone (40 mg/kg body weight) was intraperitoneally (i.p.) injected into non-irradiated or γ-irradiated (6.5 Gy whole-body γ-irradiation) solid Ehrlich carcinoma-bearing mice for 30 consecutive days. Investigations included molecular targets involved in proliferation, inflammation, angiogenesis, and tumor invasiveness. Treatment with apigenin and/or cryptotanshinone significantly suppressed the growth of solid Ehrlich carcinoma tumors and demonstrated a synergistic radiosensitizing efficacy together with γ-irradiation. These effects were achieved through downregulating the expression of angiogenic and lymphangiogenic regulators, including signal transducer and activator of transcription 3, vascular endothelial growth factor C, and tumor necrosis factor alpha, suppressing matrix metalloproteinase-2 and -9 activities, which play a key role in tumor invasion and metastasis, and enhancing apoptosis via inducing cleaved caspase-3 and granzyme B levels. Histological findings of solid Ehrlich carcinoma tumors verified the recorded data. In conclusion, a synergistic radiosensitizing efficacy for apigenin and cryptotanshinone was demonstrated against Ehrlich carcinoma in the current in vivo murine model, representing therefore a potential therapeutic strategy for increasing the radiation response of solid tumors.
[Mh] Termos MeSH primário: Apigenina/administração & dosagem
Carcinoma de Ehrlich/tratamento farmacológico
Carcinoma de Ehrlich/radioterapia
Radiossensibilizantes/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Apoptose/efeitos dos fármacos
Apoptose/efeitos da radiação
Carcinoma de Ehrlich/patologia
Proliferação Celular/efeitos dos fármacos
Proliferação Celular/efeitos da radiação
Modelos Animais de Doenças
Feminino
Raios gama
Seres Humanos
Camundongos
Fenantrenos/administração & dosagem
Irradiação Corporal Total
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Phenanthrenes); 0 (Radiation-Sensitizing Agents); 5E9SXT166N (cryptotanshinone); 7V515PI7F6 (Apigenin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171013
[St] Status:MEDLINE
[do] DOI:10.1177/1010428317728480


  8 / 8901 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28982844
[Au] Autor:Hutchinson J; Marignol L
[Ad] Endereço:Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity College Dublin, Dublin, Ireland.
[Ti] Título:Clinical Potential of Statins in Prostate Cancer Radiation Therapy.
[So] Source:Anticancer Res;37(10):5363-5372, 2017 10.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: Statins are cholesterol- lowering drugs that have been shown to possess anti-tumour properties. Observational studies have shown that 3-hydroxy-3-methlyglutaryl coenzyme A reductase inhibitor (statin) use may be associated with reduced prostate cancer risk. Preclinical studies suggest that statins possess anticancer and radiosensitising properties. This review aims to determine the impact of statin use in the efficacy of radiation therapy and the therapeutic window in prostate cancer. MATERIALS AND METHODS: The scientific databases PubMed, Science Direct, EMBASE, Cochrane Collaboration, and Google Scholar were searched for articles identifying statin use in histologically confirmed prostate cancer treated with external beam radiation therapy. RESULTS: Improvement was observed in freedom from biochemical failure (91% vs. 79%), relapse free survival (72% vs. 69%), distant metastasis free survival (96% vs. 94%), and prostate-specific antigen (PSA) relapse free survival (89% vs. 83%) with statin use, however this did not translate into an overall survival benefit for patients. Conflicting data concerning clinical outcomes reduce the integrity of these findings. The literature supports the radiosensitising properties of statins and their potential antitumor effects in prostate cancer. CONCLUSION: Statin use in prostate cancer presents many obstacles yet to be overcome, which warrant attention prior to the routine implementation of statins in treatment regimes. However, there is evidence to support their beneficial use.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Quimiorradioterapia/métodos
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Neoplasias da Próstata/terapia
Radiossensibilizantes/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/efeitos adversos
Quimiorradioterapia/efeitos adversos
Progressão da Doença
Intervalo Livre de Doença
Seres Humanos
Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos
Calicreínas/sangue
Masculino
Metástase Neoplásica
Recidiva Local de Neoplasia
Antígeno Prostático Específico/sangue
Neoplasias da Próstata/sangue
Neoplasias da Próstata/mortalidade
Neoplasias da Próstata/patologia
Radiossensibilizantes/efeitos adversos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Radiation-Sensitizing Agents); EC 3.4.21.- (Kallikreins); EC 3.4.21.- (kallikrein-related peptidase 3, human); EC 3.4.21.77 (Prostate-Specific Antigen)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171007
[St] Status:MEDLINE


  9 / 8901 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28927529
[Au] Autor:Berardinelli F; Coluzzi E; Sgura A; Antoccia A
[Ad] Endereço:Dipartimento di Scienze, Università Roma Tre, Rome Italy; Istituto Nazionale di Fisica Nucleare, INFN, Sezione di Roma Tre, Rome, Italy. Electronic address: francesco.berardinelli@uniroma3.it.
[Ti] Título:Targeting telomerase and telomeres to enhance ionizing radiation effects in in vitro and in vivo cancer models.
[So] Source:Mutat Res;773:204-219, 2017 Jul.
[Is] ISSN:1873-135X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:One of the hallmarks of cancer consists in the ability of tumor cells to divide indefinitely, and to maintain stable telomere lengths throughout the activation of specific telomere maintenance mechanisms (TMM). Therefore in the last fifteen years, researchers proposed to target telomerase or telomeric structure in order to block limitless replicative potential of cancer cells providing a fascinating strategy for a broad-spectrum cancer therapy. In the present review, we report in vitro and in vivo evidence regarding the use of chemical agents targeting both telomerase or telomere structure and showing promising antitumor effects when used in combination with ionizing radiation (IR). RNA interference, antisense oligonucleotides (e.g., GRN163L), non-nucleoside inhibitors (e.g., BIBR1532) and nucleoside analogs (e.g., AZT) represent some of the most potent strategies to inhibit telomerase activity used in combination with IR. Furthermore, radiosensitizing effects were demonstrated also for agents acting directly on the telomeric structure such as G4-ligands (e.g., RHPS4 and Telomestatin) or telomeric-oligos (T-oligos). To date, some of these compounds are under clinical evaluation (e.g., GRN163L and KML001). Advantages of Telomere/Telomerase Targeting Compounds (T/TTCs) coupled with radiotherapy may be relevant in the treatment of radioresistant tumors and in the development of new optimized treatment plans with reduced dose adsorbed by patients and consequent attenuation of short- end long-term side effects. Pros and cons of possible future applications in cancer therapy based on the combination of T/TCCs and radiation treatment are discussed.
[Mh] Termos MeSH primário: Neoplasias/tratamento farmacológico
Neoplasias/radioterapia
Radiação Ionizante
Telomerase/metabolismo
Telômero/metabolismo
[Mh] Termos MeSH secundário: Aminobenzoatos/farmacologia
Animais
Linhagem Celular Tumoral
Proliferação Celular/efeitos dos fármacos
Proliferação Celular/efeitos da radiação
Modelos Animais de Doenças
Homeostase/efeitos dos fármacos
Homeostase/efeitos da radiação
Seres Humanos
Naftalenos/farmacologia
Oligonucleotídeos/farmacologia
Interferência de RNA
Radiossensibilizantes/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Aminobenzoates); 0 (BIBR 1532); 0 (GRN163L peptide); 0 (Naphthalenes); 0 (Oligonucleotides); 0 (Radiation-Sensitizing Agents); EC 2.7.7.49 (Telomerase)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170921
[St] Status:MEDLINE


  10 / 8901 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28873460
[Au] Autor:Feldman LA; Fabre MS; Grasso C; Reid D; Broaddus WC; Lanza GM; Spiess BD; Garbow JR; McConnell MJ; Herst PM
[Ad] Endereço:Department of Neurosurgery, Virginia Commonwealth University, Richmond, VA United States of America.
[Ti] Título:Perfluorocarbon emulsions radiosensitise brain tumors in carbogen breathing mice with orthotopic GL261 gliomas.
[So] Source:PLoS One;12(9):e0184250, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Tumour hypoxia limits the effectiveness of radiation therapy. Delivering normobaric or hyperbaric oxygen therapy elevates pO2 in both tumour and normal brain tissue. However, pO2 levels return to baseline within 15 minutes of stopping therapy. AIM: To investigate the effect of perfluorocarbon (PFC) emulsions on hypoxia in subcutaneous and intracranial mouse gliomas and their radiosensitising effect in orthotopic gliomas in mice breathing carbogen (95%O2 and 5%CO2). RESULTS: PFC emulsions completely abrogated hypoxia in both subcutaneous and intracranial GL261 models and conferred a significant survival advantage orthotopically (Mantel Cox: p = 0.048) in carbogen breathing mice injected intravenously (IV) with PFC emulsions before radiation versus mice receiving radiation alone. Carbogen alone decreased hypoxia levels substantially and conferred a smaller but not statistically significant survival advantage over and above radiation alone. CONCLUSION: IV injections of PFC emulsions followed by 1h carbogen breathing, radiosensitises GL261 intracranial tumors.
[Mh] Termos MeSH primário: Neoplasias Encefálicas/tratamento farmacológico
Dióxido de Carbono/uso terapêutico
Fluorcarbonetos/uso terapêutico
Glioma/tratamento farmacológico
Oxigênio/uso terapêutico
Radiossensibilizantes/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Neoplasias Encefálicas/patologia
Dióxido de Carbono/farmacologia
Modelos Animais de Doenças
Relação Dose-Resposta a Droga
Emulsões
Fluorcarbonetos/farmacologia
Glioma/patologia
Camundongos Endogâmicos C57BL
Oxigênio/farmacologia
Radiossensibilizantes/farmacologia
Análise de Sobrevida
Hipóxia Tumoral/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Emulsions); 0 (Fluorocarbons); 0 (Radiation-Sensitizing Agents); 142M471B3J (Carbon Dioxide); 8063-77-2 (carbogen); S88TT14065 (Oxygen)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170906
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0184250



página 1 de 891 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde